Drugs / Genetically Engineered NY-ESO-1-specific T Lymphocytes
Genetically Engineered NY-ESO-1-specific T Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03017131 | Dec 2017 → Mar 2020 overdue | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genetically Engineered NY-ESO-1-specific T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03017131 ↗ |
| Action | Deplete | “genetically modified to recognize and attack tumor cells” NCT03017131 ↗ |
| Modality | Cell therapy | “genetically engineered NY-ESO-1-specific T lymphocytes” NCT03017131 ↗ |
| Route | Intravenous | “Given IV and IP” NCT03017131 ↗ |
| Route | Other | “Given IV and IP” NCT03017131 ↗ |